Jacqueline E Sherbuk1, Emi E Okamoto2, Morgan A Marks3, Enzo Fortuny4, Eva H Clark5, Gerson Galdos-Cardenas6, Angel Vasquez-Villar7, Antonio B Fernandez8, Thomas C Crawford9, Rose Q Do10, Jorge Luis Flores-Franco4, Rony Colanzi4, Robert H Gilman11, Caryn Bern12. 1. Yale-New Haven Hospital, New Haven, CT, USA. 2. Hospital of University of Pennsylvania, Philadelphia, PA, USA. 3. Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA; Merck and Co. Inc., West Point, PA, USA. 4. Universidad Catolica Boliviana, Santa Cruz, Plurinational State of Bolivia. 5. Baylor College of Medicine, Houston, TX, USA. 6. Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA; Universidad Catolica Boliviana, Santa Cruz, Plurinational State of Bolivia. 7. Hospital Nacional Guillermo Almenara Ingoyen, Lima, Peru. 8. Hartford Hospital, Hartford, CT, USA. 9. University of Michigan School of Medicine, Ann Arbor, MI, USA. 10. Veterans Affairs Medical Center and University of Colorado School of Medicine, Denver, CO, USA. 11. Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA. 12. University of California San Francisco, San Francisco, CA, USA. Electronic address: Caryn.Bern2@UCSF.EDU.
Abstract
BACKGROUND: Chagas cardiomyopathy is a chronic sequela of infection by the parasite, Trypanosoma cruzi. Advanced cardiomyopathy is associated with a high mortality rate, and clinical characteristics have been used to predict mortality risk. Though multiple biomarkers have been associated with Chagas cardiomyopathy, it is unknown how these are related to survival. OBJECTIVES: This study aimed to identify biomarkers associated with mortality in individuals with severe Chagas cardiomyopathy in an urban Bolivian hospital. METHODS: The population included individuals with and without T. cruzi infection recruited in an urban hospital in Santa Cruz, Bolivia. Baseline characteristics, electrocardiogram findings, medications, and serum cardiac biomarker levels (B-type natriuretic peptide [BNP], N-terminal pro-B-type natriuretic peptide [NT-proBNP], creatine kinase-myocardial band [CK-MB], troponin I, matrix metalloproteinase [MMP]-2, MMP-9, tissue inhibitor of metalloproteinases [TIMP] 1 and 2, transforming growth factor [TGF] beta 1 and 2) were ascertained. Echocardiograms were performed on those with cardiac symptoms or electrocardiogram abnormalities at baseline. Participants were contacted approximately 1 year after initial evaluation; deaths were reported by family members. Receiver-operating characteristic curves (ROC) were used to optimize cutoff values for each marker. For markers with area under the curve (AUC) >0.55, Cox proportional hazards models were performed to determine the hazards ratio (HR) and 95% confidence interval (CI) for the association of each marker with mortality. RESULTS: The median follow-up time was 14.1 months (interquartile range 12.5, 16.7). Of 254 individuals with complete cardiac data, 220 (87%) had follow-up data. Of 50 patients with severe Chagas cardiomyopathy at baseline, 20 (40%) had died. Higher baseline levels of BNP (HR: 3.1, 95% CI: 1.2 to 8.4), NT-proBNP (HR: 4.4, 95% CI: 1.8 to 11.0), CK-MB (HR: 3.3, 95% CI: 1.3 to 8.0), and MMP-2 (HR: 4.2, 95% CI: 1.5 to 11.8) were significantly associated with subsequent mortality. CONCLUSIONS: Severe Chagas cardiomyopathy is associated with high short-term mortality. BNP, NT-proBNP, CK-MB, and MMP-2 have added predictive value for mortality, even in the presence of decreased ejection fraction and other clinical signs of congestive heart failure.
BACKGROUND: Chagas cardiomyopathy is a chronic sequela of infection by the parasite, Trypanosoma cruzi. Advanced cardiomyopathy is associated with a high mortality rate, and clinical characteristics have been used to predict mortality risk. Though multiple biomarkers have been associated with Chagas cardiomyopathy, it is unknown how these are related to survival. OBJECTIVES: This study aimed to identify biomarkers associated with mortality in individuals with severe Chagas cardiomyopathy in an urban Bolivian hospital. METHODS: The population included individuals with and without T. cruzi infection recruited in an urban hospital in Santa Cruz, Bolivia. Baseline characteristics, electrocardiogram findings, medications, and serum cardiac biomarker levels (B-type natriuretic peptide [BNP], N-terminal pro-B-type natriuretic peptide [NT-proBNP], creatine kinase-myocardial band [CK-MB], troponin I, matrix metalloproteinase [MMP]-2, MMP-9, tissue inhibitor of metalloproteinases [TIMP] 1 and 2, transforming growth factor [TGF] beta 1 and 2) were ascertained. Echocardiograms were performed on those with cardiac symptoms or electrocardiogram abnormalities at baseline. Participants were contacted approximately 1 year after initial evaluation; deaths were reported by family members. Receiver-operating characteristic curves (ROC) were used to optimize cutoff values for each marker. For markers with area under the curve (AUC) >0.55, Cox proportional hazards models were performed to determine the hazards ratio (HR) and 95% confidence interval (CI) for the association of each marker with mortality. RESULTS: The median follow-up time was 14.1 months (interquartile range 12.5, 16.7). Of 254 individuals with complete cardiac data, 220 (87%) had follow-up data. Of 50 patients with severe Chagas cardiomyopathy at baseline, 20 (40%) had died. Higher baseline levels of BNP (HR: 3.1, 95% CI: 1.2 to 8.4), NT-proBNP (HR: 4.4, 95% CI: 1.8 to 11.0), CK-MB (HR: 3.3, 95% CI: 1.3 to 8.0), and MMP-2 (HR: 4.2, 95% CI: 1.5 to 11.8) were significantly associated with subsequent mortality. CONCLUSIONS: Severe Chagas cardiomyopathy is associated with high short-term mortality. BNP, NT-proBNP, CK-MB, and MMP-2 have added predictive value for mortality, even in the presence of decreased ejection fraction and other clinical signs of congestive heart failure.
Authors: Luciana G C Vilas Boas; Reinaldo B Bestetti; Ana Paula Otaviano; Augusto Cardinalli-Neto; Paulo R Nogueira Journal: Int J Cardiol Date: 2012-02-23 Impact factor: 4.164
Authors: Alline Maria Beleigoli; Antonio Luiz Ribeiro; Maria de Fátima H Diniz; Maria Fernanda Lima-Costa; Eric Boersma Journal: Int J Cardiol Date: 2012-10-08 Impact factor: 4.164
Authors: Maria Fernanda Lima-Costa; Cibele C Cesar; Sérgio Viana Peixoto; Antonio Luiz P Ribeiro Journal: Am J Epidemiol Date: 2010-06-25 Impact factor: 4.897
Authors: Norma Leticia Bautista-López; Carlos A Morillo; Patricio López-Jaramillo; Roberto Quiroz; Carlos Luengas; Sandra Y Silva; Jacques Galipeau; Manoj Mathew Lalu; Richard Schulz Journal: Am Heart J Date: 2013-02-15 Impact factor: 4.749
Authors: S Frantz; S Störk; K Michels; M Eigenthaler; G Ertl; J Bauersachs; C E Angermann Journal: Eur J Heart Fail Date: 2008-03-17 Impact factor: 15.534
Authors: Erik Hedström; Karin Aström-Olsson; Hans Ohlin; Fredrik Frogner; Marcus Carlsson; Therese Billgren; Stefan Jovinge; Peter Cain; Galen S Wagner; Håkan Arheden Journal: Scand Cardiovasc J Date: 2007-01 Impact factor: 1.589
Authors: Jefferson Luis Vieira; Fábio Rocha Fernandes Távora; Maria Gyslane Vasconcelos Sobral; Glauber Gean Vasconcelos; Germana Porto Linhares Almeida; Juliana Rolim Fernandes; Laura Leite da Escóssia Marinho; Daniel Francisco de Mendonça Trompieri; João David De Souza Neto; Juan Alberto Cosquillo Mejia Journal: Curr Cardiol Rep Date: 2019-02-12 Impact factor: 3.955
Authors: Daniel Musikant; Romina Higa; Cristina E Rodríguez; Martin M Edreira; Oscar Campetella; Alicia Jawerbaum; María S Leguizamón Journal: Biochimie Date: 2021-04-20 Impact factor: 4.079
Authors: Aline Luciano Horta; Ana Luisa Junqueira Leite; G Paula Costa; Vivian Paulino Figueiredo; André Talvani Journal: Biomed Res Int Date: 2017-03-09 Impact factor: 3.411
Authors: Eduardo Ov Curvo; Roberto R Ferreira; Fabiana S Madeira; Gabriel F Alves; Mayara C Chambela; Veronica G Mendes; Luiz Henrique C Sangenis; Mariana C Waghabi; Roberto M Saraiva Journal: Mem Inst Oswaldo Cruz Date: 2018-02-19 Impact factor: 2.743
Authors: Michael Rowe; Jonathan Melnick; Robert Gerwien; Joseph B Legutki; Jessica Pfeilsticker; Theodore M Tarasow; Kathryn F Sykes Journal: PLoS Negl Trop Dis Date: 2017-09-05
Authors: Steven J Clipman; Josephine Henderson-Frost; Katherine Y Fu; Caryn Bern; Jorge Flores; Robert H Gilman Journal: PLoS One Date: 2018-02-13 Impact factor: 3.240
Authors: Angelica Martins Batista; Lucia Elena Alvarado-Arnez; Silvia Marinho Alves; Gloria Melo; Isabela Resende Pereira; Leonardo Alexandre de Souza Ruivo; Andrea Alice da Silva; Daniel Gibaldi; Thayse do E S Protásio da Silva; Virginia Maria Barros de Lorena; Adriene Siqueira de Melo; Ana Karine de Araújo Soares; Michelle da Silva Barros; Vláudia Maria Assis Costa; Cynthia C Cardoso; Antonio G Pacheco; Cristina Carrazzone; Wilson Oliveira; Milton Ozório Moraes; Joseli Lannes-Vieira Journal: Front Immunol Date: 2018-04-11 Impact factor: 7.561